PD-1 Targeted Nanoparticles Inhibit Activated T Cells and Alleviate Autoimmunity via Suppression of Cellular Energy Metabolism Mediated by PKM2

References

• Jones EL, Laidlaw SM, Dustin LB. TRIM21/Ro52 - Roles in innate immunity and autoimmune disease. Front Immunol. 2021;12:738473.
   PubMed Web of Science ®Google Scholar
• Bentley ER, Little SR. Local delivery strategies to restore immune homeostasis in the context of inflammation. Adv Drug Deliv Rev. 2021;178:113971.
   PubMed Web of Science ®Google Scholar
• Raverdeau M, Christofi M, Malara A, et al. Retinoic acid-induced autoantigen-specific type 1 regulatory T cells suppress autoimmunity. EMBO Rep. 2019;20(5):e47121.
   PubMed Web of Science ®Google Scholar
• Horai R, Caspi RR. Microbiome and Autoimmune Uveitis. Front Immunol. 2019;10:232.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Su G, Kijlstra A, Yang P. Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis. Prog Retin Eye Res. 2021;80:100866.
   PubMed Web of Science ®Google Scholar
• Bertrand PJ, Jamilloux Y, Kodjikian L, et al. Quality of life in patients with uveitis: data from the ULISSE study (Uveitis: cLInical and medico-economic evaluation of a Standardised Strategy for the Etiological diagnosis). Br J Ophthalmol. 2021;105(7):935–940.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513.
   PubMed Web of Science ®Google Scholar
• Shen Z, Huang W, Liu J, Tian J, Wang S, Rui K. Effects of Mesenchymal Stem Cell-Derived Exosomes on Autoimmune Diseases. Front Immunol. 2021;12:749192.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–242.
   PubMed Web of Science ®Google Scholar
• keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883–895.
   PubMed Web of Science ®Google Scholar
• Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 2009;10(11):1185–1192.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu Z, Tian M, et al. The altered PD-1/PD-L1 pathway delivers the ‘one-two punch’ effects to promote the Treg/Th17 imbalance in pre-eclampsia. Cell Mol Immunol. 2018;15(7):710–723.
   PubMed Web of Science ®Google Scholar
• Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003;198(1):63–69.
   PubMed Web of Science ®Google Scholar
• Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255–1268.
   PubMed Web of Science ®Google Scholar
• Zhao P, Wang P, Dong S, et al. Depletion of PD-1-positive cells ameliorates autoimmune disease. Nat Biomed Eng. 2019;3(4):292–305.
   PubMed Web of Science ®Google Scholar
• Liu X, Diedrichs-Möhring M, Wildner G. The Role of IFN-alpha in Experimental and Clinical Uveitis. Ocul Immunol Inflamm. 2019;27(1):23–33.
   PubMed Web of Science ®Google Scholar
• Wu S, Ma R, Zhong Y, et al. Deficiency of IL-27 Signaling Exacerbates Experimental Autoimmune Uveitis with Elevated Uveitogenic Th1 and Th17 Responses. Int J Mol Sci. 2021;22(14):7517.
   PubMed Web of Science ®Google Scholar
• Geltink RIK, Kyle RL, Pearce EL. Unraveling the Complex Interplay Between T Cell Metabolism and Function. Annu Rev Immunol. 2018;36:461–488.
   PubMed Web of Science ®Google Scholar
• Li YH, Li XF, Liu JT, et al. PKM2, a potential target for regulating cancer. Gene. 2018;668:48–53.
   PubMed Web of Science ®Google Scholar
• Michalek RD, Gerriets VA, Jacobs SR, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. 2011;186(6):3299–3303.
   PubMed Web of Science ®Google Scholar
• Lunt SY, Muralidhar V, Hosios AM, et al. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol Cell. 2015;57(1):95–107.
   PubMed Web of Science ®Google Scholar
• Angiari S, Runtsch MC, Sutton CE, et al. Pharmacological Activation of Pyruvate Kinase M2 Inhibits CD4+ T Cell Pathogenicity and Suppresses Autoimmunity. Cell Metab. 2020;31(2):391–405.e8.
   PubMed Web of Science ®Google Scholar
• Seki SM, Posyniak K, McCloud R, et al. Modulation of PKM activity affects the differentiation of TH17 cells. Sci Signal. 2020;13(655):eaay9217.
   PubMed Web of Science ®Google Scholar
• Dhanesha N, Patel RB, Doddapattar P, et al. PKM2 promotes neutrophil activation and cerebral thrombo-inflammation: therapeutic implications for ischemic stroke. Blood. 2021;1:453.
   Google Scholar
• Zhu S, Guo Y, Zhang X, et al. Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. Cancer Lett. 2021;503:240–248.
   PubMed Web of Science ®Google Scholar
• Dai H, Zeng W, Luo H. C-MET-dependent signal transduction mediates retinoblastoma growth by regulating PKM2 nuclear translocation. Cell Biochem Funct. 2020;38(2):204–212.
   PubMed Web of Science ®Google Scholar
• Wong N, Ojo D, Yan J, Tang D. PKM2 contributes to cancer metabolism. Cancer Lett. 2015;356(2Pt A):184–191.
   PubMed Web of Science ®Google Scholar
• Anastasiou D, Yu Y, Israelsen WJ, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012;8(10):839–847.
   PubMed Web of Science ®Google Scholar
• Jin S, Gao J, Yang R, et al. A baicalin-loaded coaxial nanofiber scaffold regulated inflammation and osteoclast differentiation for vascularized bone regeneration. Bioact Mater. 2021;8:559–572.
   PubMed Web of Science ®Google Scholar
• Feng X, Xu W, Li Z, Song W, Ding J, Chen X. Immunomodulatory Nanosystems. Adv Sci. 2019;6(17):1900101.
   Web of Science ®Google Scholar
• Pan W, Zhu S, Dai D, et al. MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis. Nat Commun. 2015;6:7096.
   PubMed Web of Science ®Google Scholar
• McHugh MD, Park J, Uhrich R, Gao W, Horwitz DA, Fahmy TM. Paracrine co-delivery of TGF-β and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells. Biomaterials. 2015;59:172–181.
   PubMed Web of Science ®Google Scholar
• Jiang G, Huang Z, Yuan Y, Tao K, Feng W. Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells. J Hematol Oncol. 2021;14(1):139.
   PubMed Web of Science ®Google Scholar
• Sarkar Siddique JC, Chow L. Gold Nanoparticles for Drug Delivery and Cancer Therapy. Applied Science. 2020;10(11):3824.
   Web of Science ®Google Scholar
• Sarkar Siddique JC, Chow L. Application of Nanomaterials in Biomedical Imaging and Cancer Therapy. Nanomaterials. 2020;10(9):1700.
   Web of Science ®Google Scholar
• Sadeghi AR, Nokhasteh S, Molavi AM, et al. Surface modification of electrospun PLGA scaffold with collagen for bioengineered skin substitutes. Mater Sci Eng C Mater Biol Appl. 2016;68:995.
   PubMed Web of Science ®Google Scholar
• Wang Q, Sui G, Wu X, et al. A sequential targeting nanoplatform for anaplastic thyroid carcinoma theranostics. Acta Biomater. 2020;102:367–383.
   PubMed Web of Science ®Google Scholar
• Zhang F, Song Q, Huang X, et al. A Novel High Mechanical Property PLGA Composite Matrix Loaded with Nanodiamond-Phospholipid Compound for Bone Tissue Engineering. ACS Appl Mater Interfaces. 2016;8(2):1087–1097.
   PubMed Web of Science ®Google Scholar
• Lee S, Han D, Kang HG, et al. Intravenous sustained-release nifedipine ameliorates nonalcoholic fatty liver disease by restoring autophagic clearance. Biomaterials. 2019;197:1–11.
   PubMed Web of Science ®Google Scholar
• Abbas AK, Trotta E, Simeonov R, Marson A, Bluestone JA. Revisiting IL-2: biology and therapeutic prospects. Sci Immunol. 2018;3(25):eaat1482.
   PubMed Web of Science ®Google Scholar
• Guedes MC, Borrego LM, Proença RD. Roles of interleukin-17 in uveitis. Indian J Ophthalmol. 2016;64(9):628–634.
   PubMed Web of Science ®Google Scholar
• Luger D, Silver PB, Tang J, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector T category. J Exp Med. 2008;205(4):799–810.
   PubMed Web of Science ®Google Scholar
• Shahab MA, Mir TA, Zafar S. Optimising drug therapy for non-infectious uveitis. Int Ophthalmol. 2019;39(7):1633–1650.
   PubMed Web of Science ®Google Scholar
• Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33(4):289–294.
   PubMed Web of Science ®Google Scholar